Determination of HER-2 status on FNAC material from breast carcinomas using in situ hybridization with dual chromogen visualization with silver enhancement (dual SISH)
- PMID: 20976182
- PMCID: PMC2955822
- DOI: 10.4103/1742-6413.70968
Determination of HER-2 status on FNAC material from breast carcinomas using in situ hybridization with dual chromogen visualization with silver enhancement (dual SISH)
Abstract
During the last years, HER-2 status kits and protocols for chromogen visualization of hybridization signals have come on the market. The first generation using chromogen visualization used single color probes. The second generation, now emerging on the market, uses dual chromogen visualization. The aim of this study has been to test a new dual color chromogen kit (Ventana INFORM HER2 Dual Colour ISH Roche(®)) and compare the results with our in-house method(s). The material consisted primarily of cytological material from invasive breast carcinomas in 49 women. Dual SISH was done on all 49 cytological and histological specimens. The histological specimens were treated according to the manufacturer's recommendations. The procedure was modified in several steps in order to adapt it to the cytological material. Hybridization failed in two cytological specimens. Dual SISH showed concordant results on cytological and histological material as to amplified/not amplified. The included cases had the same HER-2 expression in the invasive and the in situ components on histology. Four IDC showed HER-2 amplification (8.5%). Polysomy was found in two cases. All dual SISH results except for one concurred with the results of the in-house method(s) (1/47=2.1%). The dual SISH is suitable for cytological examination of HER-2 status. The protocol must be optimized for cytological material.
Keywords: Breast carcinoma; HER-2; dual SISH; fine needle aspiration cytology; in situ hybridization; liquid based material.
Figures





Similar articles
-
Determination of the Her-2/neu gene amplification status in cytologic breast cancer specimens using automated silver-enhanced in-situ hybridization (SISH).Am J Surg Pathol. 2010 Aug;34(8):1180-5. doi: 10.1097/PAS.0b013e3181e70e15. Am J Surg Pathol. 2010. PMID: 20661016
-
Evaluation of automated silver-enhanced in situ hybridization (SISH) for detection of HER2 gene amplification in breast carcinoma excision and core biopsy specimens.Histopathology. 2009 Jan;54(2):248-53. doi: 10.1111/j.1365-2559.2008.03185.x. Histopathology. 2009. PMID: 19207950
-
Comparison of automated silver enhanced in situ hybridisation (SISH) and fluorescence ISH (FISH) for the validation of HER2 gene status in breast carcinoma according to the guidelines of the American Society of Clinical Oncology and the College of American Pathologists.Virchows Arch. 2007 Jul;451(1):19-25. doi: 10.1007/s00428-007-0424-5. Epub 2007 Jun 12. Virchows Arch. 2007. PMID: 17562074
-
Chromogenic and Silver in Situ Hybridization for Identification of HER 2 Overexpression in Breast Cancer Patients: A Systematic Review and Meta-Analysis.Appl Immunohistochem Mol Morphol. 2020 Jul;28(6):411-421. doi: 10.1097/PAI.0000000000000773. Appl Immunohistochem Mol Morphol. 2020. PMID: 31135445
-
Diagnostic value of fine needle aspirates processed by ThinPrep® for the assessment of axillary lymph node status in patients with invasive carcinoma of the breast.Cytopathology. 2013 Dec;24(6):372-6. doi: 10.1111/cyt.12022. Epub 2012 Oct 1. Cytopathology. 2013. PMID: 23020285 Review.
Cited by
-
Fine-needle aspiration cytology can play a role in neoadjuvant chemotherapy in operable breast cancer.ISRN Oncol. 2013 Jul 10;2013:935796. doi: 10.1155/2013/935796. Print 2013. ISRN Oncol. 2013. PMID: 23936675 Free PMC article.
-
Establishing a protocol for immunocytochemical staining and chromogenic in situ hybridization of Giemsa and Diff-Quick prestained cytological smears.Cytojournal. 2012;9:8. doi: 10.4103/1742-6413.94518. Epub 2012 Mar 29. Cytojournal. 2012. PMID: 22574078 Free PMC article.
-
Bright-field HER2 dual in situ hybridization (DISH) assay on breast cancer cell blocks: a comparative study with histological sections.Breast Cancer. 2016 Nov;23(6):917-921. doi: 10.1007/s12282-015-0664-1. Epub 2016 Jan 8. Breast Cancer. 2016. PMID: 26746842 Free PMC article.
-
Announcement of first time Cytojournal impact factor for 2012 coincides with Cytojournal decade celebration (2004-2013).Cytojournal. 2013 Aug 30;10:18. doi: 10.4103/1742-6413.117359. eCollection 2013. Cytojournal. 2013. PMID: 24082914 Free PMC article. No abstract available.
-
HER 2 immunohistochemistry for breast cancer cell blocks can be used in the same way as that used for histological specimens.Diagn Cytopathol. 2016 Apr;44(4):274-9. doi: 10.1002/dc.23433. Epub 2016 Jan 22. Diagn Cytopathol. 2016. PMID: 26800514 Free PMC article.
References
-
- NBCG. Blåboka. Oslo, Norwegian Breast Cancer Group. 2007
-
- Sosialdirektoratet H-o. Nasjonalt handlingsprogram med retningslinjer for diagnostikk, behandling og oppfølging av pasienter med brystkreft. In “Nasjonale faglige retningslinjer 15-1524”. 2007 (National action program and recommendations for diagnostics, treatment and follow-up of patients with breast cancer)
-
- Kocjan G. The role of breast FNAC in diagnosis and clinical management: A survey of current practice. Cytopathology. 2008;19:271–8. - PubMed
-
- Kevin CH, Benjamin RK. Fluorescence in situ hybridization in diagnostic cytology. Hum Pathol. 2007;38:1137–44. - PubMed
-
- Kim GY, Oh YL. Chromogenic in situ hybridization analysis of HER-2/neu status in cytological samples of breast carcinoma. Cytopathology. 2004;15:315–20. - PubMed
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous